Discovery
Deconstructing immunology
Uncharted depths
With the world’s leading technology for screening and mapping of natural immune responses, we test antibodies from single B cells at depths of millions of cells per day. We unlock the power of natural immunity to discover the next generation of antibody therapies.
Diversity, Speed, Throughput, Selectivity
Access to our industry-leading technology and world-class research team is something that our partners clearly value. This includes:
- Faster discovery — Hundreds of high-quality leads, from immunization to purified antibodies in as little as 3 months.
- Deeper screening — More than two orders of magnitude deeper than hybridoma methods to find ultra-rare antibodies with increased diversity.
- Versatile single-cell assays — To select rare antibodies based on cross-reactivity, specificity, competition, affinity, live-cell binding and functional properties.
- Greater diversity — Discoveries made from any tissue and any species, mining untapped antibody sources.
A fully integrated solution for antibody discovery:
Immunization
Soluble and complex proteins
immunization
Single-cell screening
Microfluidic selection from millions of cells
screening
Next-Gen Sequencing
From cell to sequence in 5 days
sequencing
Bioinformatics
Custom analysis and visualization tools
bioinformatics
Expression
Rapid expression of hundreds of antibodies
expression
Characterization
High-throughput validation of antibody properties
characterization
Through optimized immunizations and ultra-deep screening with direct cell-binding assays, we provide industry-leading antibody discovery against GPCRs and ion channels.
Difficult targets
By deep mining and functional profiling of human samples, we discover rare antibodies against viral and bacterial pathogens, and enable rational design of new vaccines.
Human antibody discovery
Our rapid microfluidic screening platform brings dramatically improved diversity and faster antibody generation to achieve successful lead selection and development.
Increased speed and antibody diversity
Direct screening of single cells eliminates the need for species-specific fusion partners. This provides access to any natural immune responses to obtain greater diversity (e.g. humans, mice, rabbits, llamas), and enables the discovery of veterinary biologics therapeutics with matching species.
Alternative species
Any Target. Any Source.
Multiple Species
species
Various Tissues
tissue
Any Class
class